THE METABOLIC SYNDROME A Reversible Life-Threatening Condition - PowerPoint PPT Presentation

1 / 18
About This Presentation
Title:

THE METABOLIC SYNDROME A Reversible Life-Threatening Condition

Description:

Diabetes. ... Diabetes.2002, 51 Suppl 1:S212-20. Bergman RN. Pathogenesis and prediction of diabetes mellitus: lessons from integrative physiology. ... – PowerPoint PPT presentation

Number of Views:527
Avg rating:3.0/5.0
Slides: 19
Provided by: MichelB52
Category:

less

Transcript and Presenter's Notes

Title: THE METABOLIC SYNDROME A Reversible Life-Threatening Condition


1
THE METABOLICSYNDROMEA Reversible
Life-Threatening Condition
  • Metabolic Syndrome and Insulin Resistance

2
Insulin Resistance (IR)
IS Insulin Sensitive Haffner SM et al. Diabetes
Care, 1999 22 562-568.
3
IR as a CVD risk factor
Bonora E. et al., Diabetes Care 2002 25(7)
1135-1141.
4
Risk of CVD rises as IR inceases
Hanley A.J. et al. Diabetes Care 2002 25
1177-1184. (San Antonio Heart Study)
5
Glucometabolic effects of insulin
NEFA Non Esterified Fatty Acids
6
Common insulin resistance (IR)
  • underlies most cases of T2DM, central obesity and
    metabolic syndrome
  • driven by overweight/obesity, as a result of
    adipokines/FFA imbalance and lipotoxicity
  • represents a ? in insulin-mediated glucose uptake
    (IMGU) and glycogen synthesis, mostly in skeletal
    muscle (responsible for the bulk of IMGU)
  • Liver IR usually present, resulting from portal
    adipokines/FFA imbalance and lipotoxicity
    associated with fatty tissue expansion
  • IR is a continuous variable often considered
    present when IMGU lt lower quartile of a normal
    control cohort

Beck-Nielsen et al. in Insulin Resistance, Kumar
ORahilly eds. 2005 John Wiley Sons, Ltd
7
Measuring Insulin Sensitivity ( Secretion )
  • reciprocal of fasting plasma insulin (FPI -1)
  • oral glucose tolerance test (OGTT)
  • Intravenous glucose tolerance test (IVGTT)
  • Homeostatic Model Assessment Continuous
    Infusion of Glucose with Model Assessment
    (HOMA-CIGMA)
  • Quantitative Insulin sensitivity ChecK Index
    (QUICKI)
  • frequently sampled IVGTT with MinMod
  • euglycemic hyperinsulinemic clamp (hyperglycemic
    clamp)
  • glucose-insulin infusion
  • Bonoras insulin tolerance test
  • insulin suppression test

Various methods are currently used to assess
insulin sensitivity. The  gold standard 
euglycemic hyperinsulinemic clamp is used for
research purposes and pharmacological studies,
and is not applicable to large numbers. At the
opposite end, the reciprocal of fasting insulin
can be used in large scale epidemiological
studies in normal glucose tolerance subjects. In
subjects with impaired glucose tolerance or type
2 diabetes, methods that provide both beta cell
function estimates and insulin sensitivity (such
as HOMA) are often preferred and increasingly
used for routine testing.
8
The next two slides illustrate two scenarios
linking obesity, insulin resistance and
components of the MetS
  • the most common scenario starts from acquired
    adipose tissue expansion in overweight-obese
    individuals, with secondary muscle IR
  • another scenario starts from muscle IR and
    intramyocellular fat accumulation, often
    associated with mitochondrial dysfunction,
    resulting in fat overflow in various organs,
    including ectopic fat deposition
  • in predisposed individuals, the common scenario
    sequence can coexist alongside genetic or
    acquired defects in myocellular metabolism or
    mitochondrial function, amplifying each other.

9
(No Transcript)
10
(No Transcript)
11
Insulin Resistance (IR) and T2DM
  • precedes hyperglycemia based in muscle/liver and
    modulated by adipo-cytokines and NEFAs
    originating from adipose tissue expansion
  • ? NEFAs availability induces ? in
    intramyocellular long chain fatty acyl-CoA
    (LCFAcyl-CoA), resulting in
  • ? insulin PIP3 PKB/Akt signaling
  • ? glucose transport (GLUT4) / phosphorylation
  • ? insulin-stimulated glycogen synthesis and
    oxidative phosphorylation (ATP synthesis)
  • ? ectopic triglycerides (intramyocellular lipids
    and intrahepatocytic lipids)
  • downregulation of PPARg coactivator-1 (PGC-1) and
    PGC-1-controlled genes (mitochondrial biogenesis
    and oxidative phosphorylation)

12
Etiology of LCFAcyl-CoA pool expansion
upstreamof the mitochondria
  • adipose tissue expansion and adipokine/FFA
    imbalance
  • ? mitochondria number, size, function, or
    combination
  • mutations (acquired or genetic) Mt DNA / or
    Nucl DNA
  • ageing, drugs, oxidative stress
  • fat overload (excess VLDL-C, dietary)
  • decreased AMPK activity
  • CPT-1 inhibition
  • Young offspring of T2DM ? fibers IIb

Hereditary IR
13
Insulin Resistance (IR) and T2DM
  • any ? in intramyocellular lipids (IMCL) and
    intrahepatocytic lipids (IHL) can cause IR
  • acquired and/or genetic mitochondrial dysfunction
    (MD) and oxidation associated with IMCL and IHL
    in subjects at risk for T2DM and in T2DM
  • abnormalities can combine MD ? ?
    Intramyocellular Lipids Intrahepatic Lipids
    (IMCL-IHL) ? ? lipid oxidation and IR, amplifying
    each other (vicious cycle)
  • IR may start primarily as MD in genetic IR, or,
    more commonly, from increased IMCL in
    environmental-nutritional IR associated with
    overweight-obesity
  • quantitative or qualitative sarcopenia secondary
    to reduced anabolic-anticatabolic effects of
    insulin in IR subjects

14
Insulin Sensitivity (IS) x b-Cell Function (bCF)
definesa functional area that determines glucose
homeostasis
Adapted from Kahn SE, Prigeon RL, McCulloch DK,
Boyko EJ, Bergman RN, Schwartz MW, Neifing JL,
Ward WK, Beard JC, Palmer JP, et al.
Quantification of the relationship between
insulin sensitivity and beta-cell function in
human subjects. Evidence for a hyperbolic
function. Diabetes. 1993, 421663-72. Bergman RN,
Ader M, Huecking K, Van Citters G. Accurate
assessment of beta-cell function the hyperbolic
correction. Diabetes.2002, 51 Suppl 1S212-20.
Bergman RN. Pathogenesis and prediction of
diabetes mellitus lessons from integrative
physiology. Mt Sinai J Med. 2002, 69280-90.
15
IS x bCF defines a functional area that
determinesglucose homeostasis
Adapted from Kahn SE, Prigeon RL, McCulloch DK,
Boyko EJ, Bergman RN, Schwartz MW, Neifing JL,
Ward WK, Beard JC, Palmer JP, et al.
Quantification of the relationship between
insulin sensitivity and beta-cell function in
human subjects. Evidence for a hyperbolic
function. Diabetes. 1993, 421663-72. Bergman RN,
Ader M, Huecking K, Van Citters G. Accurate
assessment of beta-cell function the hyperbolic
correction. Diabetes.2002, 51 Suppl 1S212-20.
Bergman RN. Pathogenesis and prediction of
diabetes mellitus lessons from integrative
physiology. Mt Sinai J Med. 2002, 69280-90.
16
IS x bCF defines a functional area that
determinesglucose homeostasis
Adapted from Kahn SE, Prigeon RL, McCulloch DK,
Boyko EJ, Bergman RN, Schwartz MW, Neifing JL,
Ward WK, Beard JC, Palmer JP, et al.
Quantification of the relationship between
insulin sensitivity and beta-cell function in
human subjects. Evidence for a hyperbolic
function. Diabetes. 1993, 421663-72. Bergman RN,
Ader M, Huecking K, Van Citters G. Accurate
assessment of beta-cell function the hyperbolic
correction. Diabetes.2002, 51 Suppl 1S212-20.
Bergman RN. Pathogenesis and prediction of
diabetes mellitus lessons from integrative
physiology. Mt Sinai J Med. 2002, 69280-90.
17
Hyperbolic relation between IS x bCF

Bonora E. et al. Diabetes Care, 2002 26 (7)
1153-1141.
18
90 of T2DM IR and MS
Adapted from International Diabetes Center (IDC),
Minneapolis, Minnesota.
Write a Comment
User Comments (0)
About PowerShow.com